ARCHIVES

ACS Prostate Cancer Recommendations Move Forward

This article is from The Cancer Letter archive.

Vol. 18 No. 32 | August 7, 1992

Download PDF Visit The Full Archive

Related Articles

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

February 26, 2010

IOM Review Of Duke Genomics Trials To Focus On Validation, Scientific Criteria

October 22, 2010

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

In Brief: Former HHS Official Could Replace Heckler, Reagan Signs Federal Cigarette Tax Extension

October 11, 1985

High-Starch Diet May Raise Risk Of Pancreatic Cancer

October 25, 2002

FDA Advisors Give Dox-SL Conditional Approval; Ok Zoladex

February 24, 1995